APA

Lukasiewicz E., Gorfine M., Freedman L. S., Pawlotsky J., Schalm S. W., Ferrari C., Zeuzem S. & Neumann A. U. (20100722). Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. : Journal of viral hepatitis.

Chicago

Lukasiewicz E, Gorfine M, Freedman L S, Pawlotsky J-M, Schalm S W, Ferrari C, Zeuzem S and Neumann A U. 20100722. Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. : Journal of viral hepatitis.

Harvard

Lukasiewicz E., Gorfine M., Freedman L. S., Pawlotsky J., Schalm S. W., Ferrari C., Zeuzem S. and Neumann A. U. (20100722). Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. : Journal of viral hepatitis.

MLA

Lukasiewicz E, Gorfine M, Freedman L S, Pawlotsky J-M, Schalm S W, Ferrari C, Zeuzem S and Neumann A U. Prediction of nonSVR to therapy with pegylated interferon-alpha2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment. : Journal of viral hepatitis. 20100722.